Abstract
Maia Mallevays, Lucie Berkovitch
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial
10.1001/jamapsychiatry.2023.4685 · 2024
Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial
10.1136/bmj-2021-067194 · 2022
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study
10.1016/j.eclinm.2020.100538 · 2020
Behaviorally-indexed distress tolerance and suicidality
10.1016/j.jpsychires.2012.02.015 · 2012
The importance of high distress tolerance in the relationship between nonsuicidal self-injury and suicide potential
10.1111/sltb.12048 · 2013
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
10.1177/0269881118798610 · 2018
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
10.1136/bmjopen-2017-016025 · 2017
Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences
10.1371/journal.pone.0322501 · 2025
The mediating roles of affect lability and experiential avoidance between distress tolerance and suicidal ideation among college students
10.1177/00332941231216671 · 2025
Risk factors for early recurrence after discontinuing lithium in bipolar disorder
10.1111/bdi.13206 · 2022
Classic hallucinogens and mystical experiences: phenomenology and neural correlates
2017
Efficacité des psychédéliques en psychiatrie, une revue systématique
10.1016/j.encep.2020.12.002 · 2021
The psychological correlates of decreased death anxiety after a near-death experience: the role of self-esteem, mindfulness, and death representations
10.1177/0022167819892107 · 2024
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study
10.1177/0269881114565144 · 2015
Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial
10.1001/jamapsychiatry.2022.2096 · 2022
Storm on predictive brain: a neurocomputational account of ketamine antidepressant effect
10.1016/j.neubiorev.2023.105410 · 2023
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review
10.1177/02698811221116926 · 2022
Case analysis of long-term negative psychological responses to psychedelics
10.1038/s41598-023-41145-x · 2023
Pivotal mental states
10.1177/0269881120959637 · 2021
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression
10.1177/02698811251346697 · 2025
Trauma focused psychotherapy in patients with suicidal ideation: a scoping review
2023
Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study
10.1176/appi.ajp.2018.17060720 · 2018
Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences
10.1177/0269881116662634 · 2016
Trial of psilocybin versus escitalopram for depression
10.1056/nejmoa2032994 · 2021
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
10.1007/s00213-017-4771-x · 2018
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
10.1073/pnas.1119598109 · 2012
REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics
10.1124/pr.118.017160 · 2019
LSD enhances suggestibility in healthy volunteers
10.1007/s00213-014-3714-z · 2015
Therapeutic-like context and relational support during psychedelic use moderate links among stress, challenging experiences, and psychological outcomes
10.1080/02791072.2026.2644857 · 2026
Matthew oram. the trials of psychedelic therapy: LSD psychotherapy in America
10.1093/ahr/rhaa270 · 2020
Benefits and risks of antipsychotic discontinuation in people with first and multi-episode psychotic disorders or with schizophrenia: why, when, how and in whom?
10.1038/s41537-025-00700-3 · 2025
Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans
10.1177/2470547020939564 · 2020
Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial
10.1001/jamapsychiatry.2020.3285 · 2021
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
10.1038/s41398-021-01706-y · 2021
Le traitement médiatique du LSD en France en 1966: de la panique morale à la fin des études cliniques
10.7202/1091460ar · 2022
History of the administration of psychedelics in France
10.3389/fpsyg.2023.1131565 · 2023
Suicide after psychedelic-assisted treatment in context
10.1016/j.psychres.2025.116399 · 2025
Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use
10.3389/fpsyg.2025.1528253 · 2025
Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – a first-in-kind open-label pilot study
10.1016/j.jad.2024.09.133 · 2025
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial
10.1038/s41591-025-04154-z · 2026
The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses
10.1038/s41398-025-03410-7 · doi-reference
Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation
10.3389/fpsyt.2020.00782 · doi-reference
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
10.1016/j.jad.2023.04.105 · doi-reference
Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial
10.1007/s00213-020-05692-9 · doi-reference
On the relationship between classic psychedelics and suicidality: a systematic review
10.1021/acsptsci.1c00024 · doi-reference
The impact of ayahuasca on suicidality: results from a randomized controlled trial
10.3389/fphar.2019.01325 · doi-reference
Strategies for resolving challenging psychedelic experiences: Insights from a mixed-methods study
10.1038/s41598-024-79931-w · doi-reference
Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis
10.1177/20451253251372449 · doi-reference
Experiential avoidance process model: a review of the mechanism for the generation and maintenance of avoidance behavior
10.5152/pcp.2024.23777 · doi-reference
Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant’s experience
10.1192/bjo.2024.768 · doi-reference
Multimodal examination of distress tolerance and suicidality in acute-care psychiatric inpatients
10.5127/jep.059416 · doi-reference
How psychedelic-assisted treatment works in the bayesian brain
10.3389/fpsyt.2022.812180 · doi-reference
The interpersonal theory of suicide
10.1037/a0018697 · doi-reference
History repeating: Guidelines to address common problems in psychedelic science
10.1177/20451253231198466 · doi-reference
The neurobiology of suicide and suicidality
10.1177/070674370304800504 · doi-reference
The molecular bases of the suicidal brain
10.1038/nrn3839 · doi-reference
DMT models the near-death experience
10.3389/fpsyg.2018.01424 · doi-reference
Psychedelics alter metaphysical beliefs
10.1038/s41598-021-01209-2 · doi-reference
Therapeutic frameworks in integration sessions in substance-assisted psychotherapy: A systematic review
10.1002/cpp.2945 · doi-reference
The association between experiential avoidance, depressive symptoms, and suicidal ideation in hospitalized older adults with functional impairments: the moderating role of resilience
10.3389/fpsyt.2025.1739518 · doi-reference
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
10.1371/journal.pone.0012412 · doi-reference
Psilocybin, a naturally occurring indoleamine compound, could be useful to prevent suicidal behaviors
10.3390/ph14121213 · doi-reference
Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial
10.1177/02698811231154852 · doi-reference
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
10.1016/j.jad.2023.01.073 · doi-reference
Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study
10.1038/s41598-025-26198-4 · doi-reference
Psilocybin desynchronizes the human brain
10.1038/s41586-024-07624-5 · doi-reference
Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A
10.1016/j.neuroscience.2008.11.036 · doi-reference
Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics
10.3389/fpsyt.2019.00896 · doi-reference
Acute effects of lysergic acid diethylamide in healthy subjects
10.1016/j.biopsych.2014.11.015 · doi-reference
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study
10.1097/jcp.0000000000000436 · doi-reference
Suicidal ideation, clinical worsening and outcomes among child participants in trauma-focused treatment
10.1007/s10802-024-01242-5 · doi-reference
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine benzoate) in healthy participants
10.1177/02698811241246857 · doi-reference
Psychedelic-augmented psychotherapy for overcoming traumatic dissociation: a review of neuroscientific and phenomenological evidence
10.1016/j.ejtd.2024.100431 · doi-reference
Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series
10.1080/20008066.2025.2609425 · doi-reference
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
10.1177/0269881116675512 · doi-reference
Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer
10.1021/acsptsci.1c00020 · doi-reference
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
10.1016/j.medj.2024.01.005 · doi-reference
Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression
10.3389/fphar.2017.00974 · doi-reference
The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis
10.1016/j.neubiorev.2025.106086 · doi-reference
Safety and risk assessment of psychedelic psychotherapy: a meta-analysis and systematic review
10.1016/j.psychres.2024.115880 · doi-reference